Le Lézard
Classified in: Health
Subject: SHA

Nordic Nanovector ASA - Share capital increase registered


OSLO, Norway, Jan. 21, 2022 /PRNewswire/ -- Reference is made to the stock exchange announcement on 19 January 2022 regarding the successful completion of Nordic Nanovector ASA's (OSE: NANOV) (the "Company") private placement of new shares (the "Private Placement").

The share capital increase pertaining to the 17,857,143 new shares, each with a nominal value of NOK 0.20, to be issued in the Private Placement (the "New Shares") has been registered in the Norwegian Register of Business Enterprises (the "NRBE") on 21 January 2022, and the Company's share capital has been increased with NOK 3,571,428.60 through the issuance of the New Shares. The New Shares are admitted to listing and made tradable on the Oslo Stock Exchange following this stock exchange announcement.

Following registration of the share capital increase related to the New Shares in the NRBE, the Company has an issued share capital of NOK 23,187,104.60, divided into 115,935,523 shares, each with a par value of NOK 0.20. Each share represents one vote in the Company's general meeting.

For further information, please contact:

Malene Brondberg, CFO 
Cell: +44 7561 431 762 
About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs. The Company aspires to become a leader in the development of CD37-targeted therapies for haematological cancers and immune diseases. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com. This information is subject to the disclose requirements pursuant to Oslo Rule Book II section 4.3.5.5 (4).

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa---share-capital-increase-registered,c3490150


These press releases may also interest you

at 04:00
The Galien Foundation Announces 2024 Prix Galien UK Award Candidates for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical Technology," "Best Pharmaceutical Product" and "Best Public Sector Innovation"
The Galien Foundation, the premier global institution dedicated to honouring innovators in life sciences, today announced the 2024 Prix Galien UK Award candidates for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical...

at 04:00
Novo Nordisk Foundation, Rigshospitalet and CNIC press release: One in three people die due to atherosclerosis: A new initiative aims to find new ways to prevent it
Globally, cardiovascular diseases due to atherosclerosis ? the build-up of plaque in arteries ? are the leading cause of death. A new Danish-Spanish research collaboration aims to develop methods to detect atherosclerosis at earlier ages and...

at 03:33
Navamedic ASA: Renewed contract for delivering antibiotics to Norwegian hospitals
Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, has received confirmation of an extension of its contract with The Norwegian Hospital Procurement Trust (Sykehusinnkjøp HF)...

at 03:00
ALLCLEAR TRAVEL RESEARCH: ONE IN FOUR PEOPLE WITH MEDICAL CONDITIONS RISK INVALIDATING THEIR TRAVEL INSURANCE WHEN TRAVELLING ABROAD
One in four people with pre-existing medical conditions (25%) say they will not declare all of their medical conditions when buying travel insurance, with 40% of these only declaring what they are currently being treated for. Of those that would not...

at 03:00
Viewpoint Teams Up with Cedar Community to Explore the Evolution of Aging in a New Episode
Viewpoint, the esteemed educational program hosted by renowned actor Dennis Quaid, is proud to announce a collaboration with Cedar Community in West Bend, Wisconsin for an upcoming episode that will shed light on the evolving journey of aging. Set to...

at 02:43
Invitation to the presentation of Calliditas´s interim report January - March 2024
Calliditas's interim report for the first quarter, January - March 2024 will be published in Swedish and English on Thursday 23 May 2024 at 07.00 a.m. CET. A combined audio cast and telephone conference with the opportunity to ask questions will be...

More news about Health...


News published on and distributed by: